parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.04 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including oligodendrocytes; strongest in platelets	0.75
chemistry Open Targets	hard to drug	0.00
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	6 Parkinson's papers of 212	0.74
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 5771

receipt 5778: MAP1A in dopamine neurons, braak

power: full sample -0.09 (p 0.728, n 18), 95% CI -0.53 to +0.40. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.13 (p 0.603, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.16 (p 0.538, n 18). could be the mix.
skeptic: leave-one-out range -0.21 to +0.03, sign flips 3; without severely affected donors -0.09 (p 0.728, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MAP1A in dopamine neurons.

case closed: nothing better to follow up.

receipt 5777: MAP1A in oligodendrocytes, braak

power: full sample -0.10 (p 0.702, n 18), 95% CI -0.54 to +0.39. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.07 (p 0.774, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.11 (p 0.664, n 18). could be the mix.
skeptic: leave-one-out range -0.24 to +0.03, sign flips 2; without severely affected donors -0.10 (p 0.702, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for MAP1A in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts